The Federal Trade Commission (FTC) is seeking public comment on follow-on biologics.
- Press Release (November 8, 2013)
- Federal Register Notice (November 8, 2013)
- Filing a Public Comment (Deadline March 1, 2014)
In addition, the FTC will hold a public workshop on December 1oth.
The Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition
The Federal Trade Commission announces it will hold a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop will focus on a few key issues, inter alia:
- The potential impact of state regulations affecting competition.
- How regulations, if necessary, might be structured to facilitate competition while still protecting patient health and safety.
- How naming may affect competition.
- The experience of other countries with follow-on biologic competition.
The Federal Register Notice poses a series of questions about which the FTC seeks public comment. The FTC will take these comments into account in its examination of these topics.
Previous Biologics Workshops and Report:
December 10, 2013 Time: 9am – 5pm
601 New Jersey Avenue, NW
The Arizona biotech community stepped into the spotlight at the 2013 Governor’s Celebration of Innovation Awards. Continue reading
SAN DIEGO, CA and PHOENIX, AZ–(Marketwired – Nov 12, 2013) – SGB Inc., an agricultural biotechnology company, and Yulex Corporation, a biomaterial company, announced today a collaboration to establish a genomics and molecular breeding platform focused on accelerating the crop improvement of Guayule as a sustainable source of biorubber that can replace traditional tropical or petroleum-based rubber for medical, consumer and industrial markets.Continue reading
Next steps: Drug development and clinical trials that could benefit patientsContinue reading
Ten Arizona Legislators Named AZBio Trailblazers By The Arizona Bioindustry Association In Recognition Of Their Leadership And Actions In Support Of The Advancement Of Arizona’s Life Science And Healthcare Industry.Continue reading
PALMS study finds dual-biomarker test to be highly sensitive and specific for cervical precancersContinue reading
FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Continue reading